Firefly Bio

San Francisco, United States

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

$94.0M raised

Feb 2024

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Firefly Bio raised?

Firefly Bio has raised $94.0M in total funding. The most recent round was Series A. The last funding was announced in February 2024.

Who are Firefly Bio's investors?

Firefly Bio's investors include Eli Lilly, Versant Ventures, MPM Capital, Decheng Capital.

Where is Firefly Bio headquartered?

Firefly Bio is headquartered in San Francisco, United States.

What does Firefly Bio do?

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

What stage is Firefly Bio at?

Firefly Bio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 15, 2024.

MLA

"Firefly Bio — Funding & Investors." VCBacked, February 15, 2024, https://www.vcbacked.co/company/firefly-bio. Accessed July 11, 2026.

APA

VCBacked. (2024). Firefly Bio — Funding & Investors. Retrieved July 11, 2026, from https://www.vcbacked.co/company/firefly-bio

Wikipedia (cite web)

{{cite web |title=Firefly Bio — Funding & Investors |url=https://www.vcbacked.co/company/firefly-bio |website=VCBacked |access-date=July 11, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 15, 2024.